Editor's note: This story was originally published Thursday, May 28.Too many red flags are flying over Hemispherx Biopharma (HEB - Get Report) to be confident in the pending U.S. approval of the company's drug for chronic fatigue syndrome.
Hemispherx's CFS Drug Is a Long Shot
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
More than 30 investing pros with skin in the game give you actionable insight and investment ideas.